Company Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for Alnylam Pharmaceuticals, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 01:34:06 2024-05-20 pm EDT			5-day change	1st Jan Change
149.7 ^USD	+0.20%		-0.26%	-21.89%

May. 07	HC Wainwright Adjusts Price Target on Alnylam Pharmaceuticals to $400 From $395, Maintains Buy Rating	MT
May. 02	Alnylam Pharmaceuticals' Q1 Non-GAAP Net Loss Narrows as Revenue Increases; 2024 Outlook Affirmed	MT

Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Companyâs lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.

Number of employees: 2,100

USD in Million	2022	Weight	2023	Weight	Delta
Ribonucleic Acid Interference Therapeutics 100.0 %	1,037	100.0 %	1,828	100.0 %	+76.23%

USD in Million	2022	Weight	2023	Weight	Delta
United States 69.8 %	616	59.4 %	1,276	69.8 %	+107.21%
Europe 21.8 %	315	30.4 %	399	21.8 %	+26.83%
Rest of the World 8.4 %	107	10.3 %	153	8.4 %	+43.31%

Managers	Title	Age	Since
Yvonne Greenstreet CEO	Chief Executive Officer	61	16-09-18
Jeffrey Poulton DFI	Director of Finance/CFO	56	19-08-12
Piyush Sharma CMP	Compliance Officer	-	22-09-20
Timothy J. Maines CTO	Chief Tech/Sci/R&D Officer	-	17-07-31
Kevin Fitzgerald CTO	Chief Tech/Sci/R&D Officer	56	04-12-31
James Bilotta CTO	Chief Tech/Sci/R&D Officer	-	15-09-30
Pushkal Garg CTO	Chief Tech/Sci/R&D Officer	56	14-10-28
Joshua Brodsky IRO	Public Communications Contact	-	21-01-31
Christine Regan Lindenboom IRC	Investor Relations Contact	43	15-08-31
Eric Green PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
David Pyott BRD	Director/Board Member	70	15-12-17
Charles Sigal BRD	Director/Board Member	72	22-08-21
Margaret Hamburg BRD	Director/Board Member	68	19-01-09
Amy Schulman CHM	Chairman	63	14-06-30
Phillip Sharp FOU	Founder	79	02-06-13
Peter Kellogg BRD	Director/Board Member	67	23-03-06
Michael Bonney BRD	Director/Board Member	65	14-12-16
Dennis Ausiello BRD	Director/Board Member	78	12-04-22
Colleen Reitan BRD	Director/Board Member	64	18-05-31
Yvonne Greenstreet CEO	Chief Executive Officer	61	16-09-18

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	126,491,778	125,969,953 ( 99.59 %)	0	99.59 %

Name	Equities	%	Valuation
Capital Research & Management Co. (World Investors) 12.97 %	16,398,889	12.97 %	2 357 M $
Capital Research & Management Co. (World Investors) 10.11 %	12,789,236	10.11 %	1 838 M $
Vanguard Fiduciary Trust Co. 9.485 %	11,994,261	9.485 %	1 724 M $
Fidelity Management & Research Co. LLC 7.882 %	9,967,120	7.882 %	1 432 M $
BlackRock Advisors LLC 5.898 %	7,458,197	5.898 %	1 072 M $
Wellington Management Co. LLP 5.736 %	7,252,907	5.736 %	1 042 M $
Wellington Management Co. LLP 5.701 %	7,209,005	5.701 %	1 036 M $
Baillie Gifford & Co. 5.510 %	6,967,097	5.510 %	1 001 M $
Baillie Gifford & Co. 5.238 %	6,623,577	5.238 %	952 M $
Dodge & Cox 3.014 %	3,811,480	3.014 %	548 M $

Alnylam Pharmaceuticals, Inc.

675 West Kendall Street Henri A. Termeer Square

02142, Cambridge

+617 551 8200

http://www.alnylam.com

address Alnylam Pharmaceuticals, Inc.(ALNY)

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

149.4 USD

Average target price

220.4 USD

Spread / Average Target

+47.51%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
ALNYLAM PHARMACEUTICALS, INC.	-21.89%	18.9B
MODERNA, INC.	+42.91%	50.93B
IQVIA HOLDINGS INC.	-0.43%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-7.20%	29.18B
ICON PUBLIC LIMITED COMPANY	+13.10%	26.02B
BIO-TECHNE CORPORATION	+7.82%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.07%	12.17B
MEDPACE HOLDINGS, INC.	+30.18%	12.16B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-6.11%	11.42B

Other Biotechnology & Medical Research